. 2009;30(6):625-30.

Emerging concepts in epithelial ovarian cancer: highlights of the 4th Canadian conference on ovarian cancer research

Affiliations

A A Tone et al. Eur J Gynaecol Oncol. 2009.

. 2009;30(6):625-30.

¹ Department of Laboratory Medicine & Pathobiology, University of Toronto, Ontario, Canada.

No abstract available

Similar articles

[The Near-Future of Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer].
Nagao S. Nagao S. Gan To Kagaku Ryoho. 2016 Feb;43(2):198-202. Gan To Kagaku Ryoho. 2016. PMID: 27093731 Japanese. No abstract available.
Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer.
Fiedor E, Zajda K, Gregoraszczuk EL. Fiedor E, et al. Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):329-336. doi: 10.21873/cgp.20091. Cancer Genomics Proteomics. 2018. PMID: 29976638 Free PMC article.
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Larbi E, Madhuri K, Essapen S, Butler-Manuel S, Tailor A, Michael A. Larbi E, et al. Clin Oncol (R Coll Radiol). 2013 Jan;25(1):75. doi: 10.1016/j.clon.2012.09.007. Epub 2012 Nov 10. Clin Oncol (R Coll Radiol). 2013. PMID: 23146339 No abstract available.
Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
Trimble EL, Thompson S, Christian MC, Minasian L. Trimble EL, et al. Oncologist. 2008 Apr;13(4):403-9. doi: 10.1634/theoncologist.2007-0058. Oncologist. 2008. PMID: 18448554 Review.
Targeting CCL11 in the treatment of ovarian cancer.
Nolen BM, Lokshin AE. Nolen BM, et al. Expert Opin Ther Targets. 2010 Feb;14(2):157-67. doi: 10.1517/14728220903512983. Expert Opin Ther Targets. 2010. PMID: 20055715 Review.